Warner Brent 4
4 · Poseida Therapeutics, Inc. · Filed Mar 2, 2023
Insider Transaction Report
Form 4
Warner Brent
President, Gene Therapy
Transactions
- Award
Common Stock
2023-03-01+92,772→ 400,653 total - Tax Payment
Common Stock
2023-03-01$5.35/sh−26,617$142,401→ 374,036 total - Award
Stock Option (Right to Buy)
2023-03-01+125,283→ 125,283 totalExercise: $5.35Exp: 2033-02-28→ Common Stock (125,283 underlying)
Footnotes (3)
- [F1]Represents shares issuable upon the vesting of restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest in four equal annual installments.
- [F2]Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on March 1, 2022.
- [F3]12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date listed in column 3 above, and the remaining shares will vest in 42 equal monthly installments thereafter.